No CYP affinity. No conceivable effects on PXR activation. However, side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Rituximab is a chimeric human-murine anti-human antigen CD20 monoclonal antibody.

Rituximab is used, alone or as part of combination therapy, in the treatment of non-Hodgkins lymphomas. It is administered as an intravenous infusion. Common adverse reactions of rituximab that can be confused with an acute porphyric attack are vomiting, nausea, obstipation, abdominal pain, dorsal pain, anxiety, agitation, insomnia and tachycardia. Side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Rituximab is metabolized as endogenous IgG. Non-CYP metabolism.

No.